OpenLegislation

Annex

United Kingdom

Original text. Later amendments are not shown.

The following entry shall be added at the end of the table in Annex I to Directive 91/414/EEC:

Further details on identity and specification of active substance are provided in the review report.

NoCommon Name, Identification NumbersIUPAC NamePurityf1 Entry into forceExpiration of inclusionSpecific provisions
‘342

Flurochloridone

CAS No: 61213-25-0

CIPAC No: 430

(3RS,4RS;3RS,4SR)-3-chloro-4-chloromethyl-1-

(α,α,α-trifluoro-m-tolyl)-2-pyrrolidone

≥ 940 g/kg.

Relevant impurities:

Toluene: max 8 g/kg

1 June 201131 May 2021

PART A

Only uses as herbicide may be authorised.

PART B

For the implementation of the uniform principles of Annex VI, the conclusions of the review report on flurochloridone, and in particular Appendices I and II thereof, as finalised in the Standing Committee on the Food Chain and Animal Health on 4 February 2011 shall be taken into account.

In this overall assessment Member States shall pay particular attention to:

  1. 1..

    the risk for non-target plants and aquatic organisms;

  2. 2..

    the protection of the groundwater, when the active substance is applied in regions with vulnerable soil and/or climatic conditions.

Conditions of authorisation shall include risk mitigation measures, where appropriate.

The Member States concerned shall ensure that the applicant submits to the Commission further confirmatory information as regards:

  1. 1..

    the relevance of impurities other than toluene;

  2. 2..

    the compliance of ecotoxicological test material with the technical specifications;

  3. 3..

    the relevance of the groundwater metabolite R42819 (R42819: (4RS)-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one);

  4. 4..

    the potential endocrine disrupting properties of flurochloridone.

The Member States concerned shall ensure that the applicant submits to the Commission the information set out in points (1) and (2) by 1 December 2011, the information set out in point (3) by 31 May 2013 and the information set out in point (4) within 2 years after the adoption of the OECD test guidelines on endocrine disruption.’

Annotations

Footnotes

f1

Further details on identity and specification of active substance are provided in the review report.